Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
- DOI
- 10.1016/j.jacc.2021.04.102
- Published
- 2021 Aug 3
- Container
- Journal of the American College of Cardiology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jacc.2021.04.102,
title = {Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.},
author = {Schwartz GG and Szarek M and Bittner VA and Diaz R and Goodman SG and Jukema JW and Landmesser U and López-Jaramillo P and Manvelian G and Pordy R and Scemama M and Sinnaeve PR and White HD and Gabriel Steg P and ODYSSEY Outcomes Committees and Investigators},
year = {2021},
journal = {Journal of the American College of Cardiology},
doi = {10.1016/j.jacc.2021.04.102},
url = {https://doi.org/10.1016/j.jacc.2021.04.102}
}RIS
TY - JOUR TI - Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. AU - Schwartz GG AU - Szarek M AU - Bittner VA AU - Diaz R AU - Goodman SG AU - Jukema JW AU - Landmesser U AU - López-Jaramillo P AU - Manvelian G AU - Pordy R AU - Scemama M AU - Sinnaeve PR AU - White HD AU - Gabriel Steg P AU - ODYSSEY Outcomes Committees and Investigators PY - 2021 JO - Journal of the American College of Cardiology DO - 10.1016/j.jacc.2021.04.102 UR - https://doi.org/10.1016/j.jacc.2021.04.102 ER -
APA
GG, S., M, S., VA, B., R, D., SG, G., JW, J., U, L., P, L., G, M., R, P., M, S., PR, S., HD, W., P, G. S., & Investigators, O. O. C. A. (2021). Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2021.04.102
Source records
- pubmed · retrieved 2026-09-26T21:47:15.682Z